Condition
Traumatic Brain Injury With Persistent Cognitive Deficits
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 4 (1)
Trial Status
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07326059Not Yet Recruiting
Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury
NCT00219245Phase 4CompletedPrimary
An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Showing all 2 trials